Global Conjugate Vaccines Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Conjugate Vaccines market size was valued at US$ 9777.7 million in 2023. With growing demand in downstream market, the Conjugate Vaccines is forecast to a readjusted size of US$ 12690 million by 2030 with a CAGR of 3.8% during review period.
The research report highlights the growth potential of the global Conjugate Vaccines market. Conjugate Vaccines are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Conjugate Vaccines. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Conjugate Vaccines market.
Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Conjugate Vaccines market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Conjugate Vaccines market. It may include historical data, market segmentation by Type (e.g., Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccines), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Conjugate Vaccines market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Conjugate Vaccines market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Conjugate Vaccines industry. This include advancements in Conjugate Vaccines technology, Conjugate Vaccines new entrants, Conjugate Vaccines new investment, and other innovations that are shaping the future of Conjugate Vaccines.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Conjugate Vaccines market. It includes factors influencing customer ' purchasing decisions, preferences for Conjugate Vaccines product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Conjugate Vaccines market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Conjugate Vaccines market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Conjugate Vaccines market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Conjugate Vaccines industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Conjugate Vaccines market.
Market Segmentation:
Conjugate Vaccines market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Conjugate Vaccines market?
What factors are driving Conjugate Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Conjugate Vaccines market opportunities vary by end market size?
How does Conjugate Vaccines break out type, application?
According to our LPI (LP Information) latest study, the global Conjugate Vaccines market size was valued at US$ 9777.7 million in 2023. With growing demand in downstream market, the Conjugate Vaccines is forecast to a readjusted size of US$ 12690 million by 2030 with a CAGR of 3.8% during review period.
The research report highlights the growth potential of the global Conjugate Vaccines market. Conjugate Vaccines are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Conjugate Vaccines. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Conjugate Vaccines market.
Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Conjugate Vaccines market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Conjugate Vaccines market. It may include historical data, market segmentation by Type (e.g., Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccines), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Conjugate Vaccines market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Conjugate Vaccines market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Conjugate Vaccines industry. This include advancements in Conjugate Vaccines technology, Conjugate Vaccines new entrants, Conjugate Vaccines new investment, and other innovations that are shaping the future of Conjugate Vaccines.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Conjugate Vaccines market. It includes factors influencing customer ' purchasing decisions, preferences for Conjugate Vaccines product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Conjugate Vaccines market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Conjugate Vaccines market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Conjugate Vaccines market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Conjugate Vaccines industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Conjugate Vaccines market.
Market Segmentation:
Conjugate Vaccines market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Monovalent Conjugate Vaccines
- Multivalent Conjugate Vaccines
- Children
- Adults
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novartis
- Neuron Biotech
- Serum Institute of India
- Pfizer
- Sanofi Pasteur
- Bharat Biotech
- Biological
- GlaxoSmithKline
- Merck
- CSL
What is the 10-year outlook for the global Conjugate Vaccines market?
What factors are driving Conjugate Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Conjugate Vaccines market opportunities vary by end market size?
How does Conjugate Vaccines break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Conjugate Vaccines Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Conjugate Vaccines by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Conjugate Vaccines by Country/Region, 2019, 2023 & 2030
2.2 Conjugate Vaccines Segment by Type
2.2.1 Monovalent Conjugate Vaccines
2.2.2 Multivalent Conjugate Vaccines
2.3 Conjugate Vaccines Sales by Type
2.3.1 Global Conjugate Vaccines Sales Market Share by Type (2019-2024)
2.3.2 Global Conjugate Vaccines Revenue and Market Share by Type (2019-2024)
2.3.3 Global Conjugate Vaccines Sale Price by Type (2019-2024)
2.4 Conjugate Vaccines Segment by Application
2.4.1 Children
2.4.2 Adults
2.5 Conjugate Vaccines Sales by Application
2.5.1 Global Conjugate Vaccines Sale Market Share by Application (2019-2024)
2.5.2 Global Conjugate Vaccines Revenue and Market Share by Application (2019-2024)
2.5.3 Global Conjugate Vaccines Sale Price by Application (2019-2024)
3 GLOBAL CONJUGATE VACCINES BY COMPANY
3.1 Global Conjugate Vaccines Breakdown Data by Company
3.1.1 Global Conjugate Vaccines Annual Sales by Company (2019-2024)
3.1.2 Global Conjugate Vaccines Sales Market Share by Company (2019-2024)
3.2 Global Conjugate Vaccines Annual Revenue by Company (2019-2024)
3.2.1 Global Conjugate Vaccines Revenue by Company (2019-2024)
3.2.2 Global Conjugate Vaccines Revenue Market Share by Company (2019-2024)
3.3 Global Conjugate Vaccines Sale Price by Company
3.4 Key Manufacturers Conjugate Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Conjugate Vaccines Product Location Distribution
3.4.2 Players Conjugate Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR CONJUGATE VACCINES BY GEOGRAPHIC REGION
4.1 World Historic Conjugate Vaccines Market Size by Geographic Region (2019-2024)
4.1.1 Global Conjugate Vaccines Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Conjugate Vaccines Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Conjugate Vaccines Market Size by Country/Region (2019-2024)
4.2.1 Global Conjugate Vaccines Annual Sales by Country/Region (2019-2024)
4.2.2 Global Conjugate Vaccines Annual Revenue by Country/Region (2019-2024)
4.3 Americas Conjugate Vaccines Sales Growth
4.4 APAC Conjugate Vaccines Sales Growth
4.5 Europe Conjugate Vaccines Sales Growth
4.6 Middle East & Africa Conjugate Vaccines Sales Growth
5 AMERICAS
5.1 Americas Conjugate Vaccines Sales by Country
5.1.1 Americas Conjugate Vaccines Sales by Country (2019-2024)
5.1.2 Americas Conjugate Vaccines Revenue by Country (2019-2024)
5.2 Americas Conjugate Vaccines Sales by Type
5.3 Americas Conjugate Vaccines Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Conjugate Vaccines Sales by Region
6.1.1 APAC Conjugate Vaccines Sales by Region (2019-2024)
6.1.2 APAC Conjugate Vaccines Revenue by Region (2019-2024)
6.2 APAC Conjugate Vaccines Sales by Type
6.3 APAC Conjugate Vaccines Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Conjugate Vaccines by Country
7.1.1 Europe Conjugate Vaccines Sales by Country (2019-2024)
7.1.2 Europe Conjugate Vaccines Revenue by Country (2019-2024)
7.2 Europe Conjugate Vaccines Sales by Type
7.3 Europe Conjugate Vaccines Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Conjugate Vaccines by Country
8.1.1 Middle East & Africa Conjugate Vaccines Sales by Country (2019-2024)
8.1.2 Middle East & Africa Conjugate Vaccines Revenue by Country (2019-2024)
8.2 Middle East & Africa Conjugate Vaccines Sales by Type
8.3 Middle East & Africa Conjugate Vaccines Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Conjugate Vaccines
10.3 Manufacturing Process Analysis of Conjugate Vaccines
10.4 Industry Chain Structure of Conjugate Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Conjugate Vaccines Distributors
11.3 Conjugate Vaccines Customer
12 WORLD FORECAST REVIEW FOR CONJUGATE VACCINES BY GEOGRAPHIC REGION
12.1 Global Conjugate Vaccines Market Size Forecast by Region
12.1.1 Global Conjugate Vaccines Forecast by Region (2025-2030)
12.1.2 Global Conjugate Vaccines Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Conjugate Vaccines Forecast by Type
12.7 Global Conjugate Vaccines Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Conjugate Vaccines Product Portfolios and Specifications
13.1.3 Novartis Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Neuron Biotech
13.2.1 Neuron Biotech Company Information
13.2.2 Neuron Biotech Conjugate Vaccines Product Portfolios and Specifications
13.2.3 Neuron Biotech Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Neuron Biotech Main Business Overview
13.2.5 Neuron Biotech Latest Developments
13.3 Serum Institute of India
13.3.1 Serum Institute of India Company Information
13.3.2 Serum Institute of India Conjugate Vaccines Product Portfolios and Specifications
13.3.3 Serum Institute of India Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Serum Institute of India Main Business Overview
13.3.5 Serum Institute of India Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Conjugate Vaccines Product Portfolios and Specifications
13.4.3 Pfizer Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Sanofi Pasteur
13.5.1 Sanofi Pasteur Company Information
13.5.2 Sanofi Pasteur Conjugate Vaccines Product Portfolios and Specifications
13.5.3 Sanofi Pasteur Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Sanofi Pasteur Main Business Overview
13.5.5 Sanofi Pasteur Latest Developments
13.6 Bharat Biotech
13.6.1 Bharat Biotech Company Information
13.6.2 Bharat Biotech Conjugate Vaccines Product Portfolios and Specifications
13.6.3 Bharat Biotech Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Bharat Biotech Main Business Overview
13.6.5 Bharat Biotech Latest Developments
13.7 Biological
13.7.1 Biological Company Information
13.7.2 Biological Conjugate Vaccines Product Portfolios and Specifications
13.7.3 Biological Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Biological Main Business Overview
13.7.5 Biological Latest Developments
13.8 GlaxoSmithKline
13.8.1 GlaxoSmithKline Company Information
13.8.2 GlaxoSmithKline Conjugate Vaccines Product Portfolios and Specifications
13.8.3 GlaxoSmithKline Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 GlaxoSmithKline Main Business Overview
13.8.5 GlaxoSmithKline Latest Developments
13.9 Merck
13.9.1 Merck Company Information
13.9.2 Merck Conjugate Vaccines Product Portfolios and Specifications
13.9.3 Merck Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Merck Main Business Overview
13.9.5 Merck Latest Developments
13.10 CSL
13.10.1 CSL Company Information
13.10.2 CSL Conjugate Vaccines Product Portfolios and Specifications
13.10.3 CSL Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 CSL Main Business Overview
13.10.5 CSL Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Conjugate Vaccines Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Conjugate Vaccines by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Conjugate Vaccines by Country/Region, 2019, 2023 & 2030
2.2 Conjugate Vaccines Segment by Type
2.2.1 Monovalent Conjugate Vaccines
2.2.2 Multivalent Conjugate Vaccines
2.3 Conjugate Vaccines Sales by Type
2.3.1 Global Conjugate Vaccines Sales Market Share by Type (2019-2024)
2.3.2 Global Conjugate Vaccines Revenue and Market Share by Type (2019-2024)
2.3.3 Global Conjugate Vaccines Sale Price by Type (2019-2024)
2.4 Conjugate Vaccines Segment by Application
2.4.1 Children
2.4.2 Adults
2.5 Conjugate Vaccines Sales by Application
2.5.1 Global Conjugate Vaccines Sale Market Share by Application (2019-2024)
2.5.2 Global Conjugate Vaccines Revenue and Market Share by Application (2019-2024)
2.5.3 Global Conjugate Vaccines Sale Price by Application (2019-2024)
3 GLOBAL CONJUGATE VACCINES BY COMPANY
3.1 Global Conjugate Vaccines Breakdown Data by Company
3.1.1 Global Conjugate Vaccines Annual Sales by Company (2019-2024)
3.1.2 Global Conjugate Vaccines Sales Market Share by Company (2019-2024)
3.2 Global Conjugate Vaccines Annual Revenue by Company (2019-2024)
3.2.1 Global Conjugate Vaccines Revenue by Company (2019-2024)
3.2.2 Global Conjugate Vaccines Revenue Market Share by Company (2019-2024)
3.3 Global Conjugate Vaccines Sale Price by Company
3.4 Key Manufacturers Conjugate Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Conjugate Vaccines Product Location Distribution
3.4.2 Players Conjugate Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR CONJUGATE VACCINES BY GEOGRAPHIC REGION
4.1 World Historic Conjugate Vaccines Market Size by Geographic Region (2019-2024)
4.1.1 Global Conjugate Vaccines Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Conjugate Vaccines Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Conjugate Vaccines Market Size by Country/Region (2019-2024)
4.2.1 Global Conjugate Vaccines Annual Sales by Country/Region (2019-2024)
4.2.2 Global Conjugate Vaccines Annual Revenue by Country/Region (2019-2024)
4.3 Americas Conjugate Vaccines Sales Growth
4.4 APAC Conjugate Vaccines Sales Growth
4.5 Europe Conjugate Vaccines Sales Growth
4.6 Middle East & Africa Conjugate Vaccines Sales Growth
5 AMERICAS
5.1 Americas Conjugate Vaccines Sales by Country
5.1.1 Americas Conjugate Vaccines Sales by Country (2019-2024)
5.1.2 Americas Conjugate Vaccines Revenue by Country (2019-2024)
5.2 Americas Conjugate Vaccines Sales by Type
5.3 Americas Conjugate Vaccines Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Conjugate Vaccines Sales by Region
6.1.1 APAC Conjugate Vaccines Sales by Region (2019-2024)
6.1.2 APAC Conjugate Vaccines Revenue by Region (2019-2024)
6.2 APAC Conjugate Vaccines Sales by Type
6.3 APAC Conjugate Vaccines Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Conjugate Vaccines by Country
7.1.1 Europe Conjugate Vaccines Sales by Country (2019-2024)
7.1.2 Europe Conjugate Vaccines Revenue by Country (2019-2024)
7.2 Europe Conjugate Vaccines Sales by Type
7.3 Europe Conjugate Vaccines Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Conjugate Vaccines by Country
8.1.1 Middle East & Africa Conjugate Vaccines Sales by Country (2019-2024)
8.1.2 Middle East & Africa Conjugate Vaccines Revenue by Country (2019-2024)
8.2 Middle East & Africa Conjugate Vaccines Sales by Type
8.3 Middle East & Africa Conjugate Vaccines Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Conjugate Vaccines
10.3 Manufacturing Process Analysis of Conjugate Vaccines
10.4 Industry Chain Structure of Conjugate Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Conjugate Vaccines Distributors
11.3 Conjugate Vaccines Customer
12 WORLD FORECAST REVIEW FOR CONJUGATE VACCINES BY GEOGRAPHIC REGION
12.1 Global Conjugate Vaccines Market Size Forecast by Region
12.1.1 Global Conjugate Vaccines Forecast by Region (2025-2030)
12.1.2 Global Conjugate Vaccines Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Conjugate Vaccines Forecast by Type
12.7 Global Conjugate Vaccines Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Conjugate Vaccines Product Portfolios and Specifications
13.1.3 Novartis Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Neuron Biotech
13.2.1 Neuron Biotech Company Information
13.2.2 Neuron Biotech Conjugate Vaccines Product Portfolios and Specifications
13.2.3 Neuron Biotech Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Neuron Biotech Main Business Overview
13.2.5 Neuron Biotech Latest Developments
13.3 Serum Institute of India
13.3.1 Serum Institute of India Company Information
13.3.2 Serum Institute of India Conjugate Vaccines Product Portfolios and Specifications
13.3.3 Serum Institute of India Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Serum Institute of India Main Business Overview
13.3.5 Serum Institute of India Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Conjugate Vaccines Product Portfolios and Specifications
13.4.3 Pfizer Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Sanofi Pasteur
13.5.1 Sanofi Pasteur Company Information
13.5.2 Sanofi Pasteur Conjugate Vaccines Product Portfolios and Specifications
13.5.3 Sanofi Pasteur Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Sanofi Pasteur Main Business Overview
13.5.5 Sanofi Pasteur Latest Developments
13.6 Bharat Biotech
13.6.1 Bharat Biotech Company Information
13.6.2 Bharat Biotech Conjugate Vaccines Product Portfolios and Specifications
13.6.3 Bharat Biotech Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Bharat Biotech Main Business Overview
13.6.5 Bharat Biotech Latest Developments
13.7 Biological
13.7.1 Biological Company Information
13.7.2 Biological Conjugate Vaccines Product Portfolios and Specifications
13.7.3 Biological Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Biological Main Business Overview
13.7.5 Biological Latest Developments
13.8 GlaxoSmithKline
13.8.1 GlaxoSmithKline Company Information
13.8.2 GlaxoSmithKline Conjugate Vaccines Product Portfolios and Specifications
13.8.3 GlaxoSmithKline Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 GlaxoSmithKline Main Business Overview
13.8.5 GlaxoSmithKline Latest Developments
13.9 Merck
13.9.1 Merck Company Information
13.9.2 Merck Conjugate Vaccines Product Portfolios and Specifications
13.9.3 Merck Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Merck Main Business Overview
13.9.5 Merck Latest Developments
13.10 CSL
13.10.1 CSL Company Information
13.10.2 CSL Conjugate Vaccines Product Portfolios and Specifications
13.10.3 CSL Conjugate Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 CSL Main Business Overview
13.10.5 CSL Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Conjugate Vaccines Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Conjugate Vaccines Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Monovalent Conjugate Vaccines
Table 4. Major Players of Multivalent Conjugate Vaccines
Table 5. Global Conjugate Vaccines Sales by Type (2019-2024) & (Units)
Table 6. Global Conjugate Vaccines Sales Market Share by Type (2019-2024)
Table 7. Global Conjugate Vaccines Revenue by Type (2019-2024) & ($ million)
Table 8. Global Conjugate Vaccines Revenue Market Share by Type (2019-2024)
Table 9. Global Conjugate Vaccines Sale Price by Type (2019-2024) & (USD/Unit)
Table 10. Global Conjugate Vaccines Sales by Application (2019-2024) & (Units)
Table 11. Global Conjugate Vaccines Sales Market Share by Application (2019-2024)
Table 12. Global Conjugate Vaccines Revenue by Application (2019-2024)
Table 13. Global Conjugate Vaccines Revenue Market Share by Application (2019-2024)
Table 14. Global Conjugate Vaccines Sale Price by Application (2019-2024) & (USD/Unit)
Table 15. Global Conjugate Vaccines Sales by Company (2019-2024) & (Units)
Table 16. Global Conjugate Vaccines Sales Market Share by Company (2019-2024)
Table 17. Global Conjugate Vaccines Revenue by Company (2019-2024) ($ Millions)
Table 18. Global Conjugate Vaccines Revenue Market Share by Company (2019-2024)
Table 19. Global Conjugate Vaccines Sale Price by Company (2019-2024) & (USD/Unit)
Table 20. Key Manufacturers Conjugate Vaccines Producing Area Distribution and Sales Area
Table 21. Players Conjugate Vaccines Products Offered
Table 22. Conjugate Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Conjugate Vaccines Sales by Geographic Region (2019-2024) & (Units)
Table 26. Global Conjugate Vaccines Sales Market Share Geographic Region (2019-2024)
Table 27. Global Conjugate Vaccines Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Conjugate Vaccines Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Conjugate Vaccines Sales by Country/Region (2019-2024) & (Units)
Table 30. Global Conjugate Vaccines Sales Market Share by Country/Region (2019-2024)
Table 31. Global Conjugate Vaccines Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Conjugate Vaccines Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Conjugate Vaccines Sales by Country (2019-2024) & (Units)
Table 34. Americas Conjugate Vaccines Sales Market Share by Country (2019-2024)
Table 35. Americas Conjugate Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas Conjugate Vaccines Revenue Market Share by Country (2019-2024)
Table 37. Americas Conjugate Vaccines Sales by Type (2019-2024) & (Units)
Table 38. Americas Conjugate Vaccines Sales by Application (2019-2024) & (Units)
Table 39. APAC Conjugate Vaccines Sales by Region (2019-2024) & (Units)
Table 40. APAC Conjugate Vaccines Sales Market Share by Region (2019-2024)
Table 41. APAC Conjugate Vaccines Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC Conjugate Vaccines Revenue Market Share by Region (2019-2024)
Table 43. APAC Conjugate Vaccines Sales by Type (2019-2024) & (Units)
Table 44. APAC Conjugate Vaccines Sales by Application (2019-2024) & (Units)
Table 45. Europe Conjugate Vaccines Sales by Country (2019-2024) & (Units)
Table 46. Europe Conjugate Vaccines Sales Market Share by Country (2019-2024)
Table 47. Europe Conjugate Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe Conjugate Vaccines Revenue Market Share by Country (2019-2024)
Table 49. Europe Conjugate Vaccines Sales by Type (2019-2024) & (Units)
Table 50. Europe Conjugate Vaccines Sales by Application (2019-2024) & (Units)
Table 51. Middle East & Africa Conjugate Vaccines Sales by Country (2019-2024) & (Units)
Table 52. Middle East & Africa Conjugate Vaccines Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa Conjugate Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa Conjugate Vaccines Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa Conjugate Vaccines Sales by Type (2019-2024) & (Units)
Table 56. Middle East & Africa Conjugate Vaccines Sales by Application (2019-2024) & (Units)
Table 57. Key Market Drivers & Growth Opportunities of Conjugate Vaccines
Table 58. Key Market Challenges & Risks of Conjugate Vaccines
Table 59. Key Industry Trends of Conjugate Vaccines
Table 60. Conjugate Vaccines Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Conjugate Vaccines Distributors List
Table 63. Conjugate Vaccines Customer List
Table 64. Global Conjugate Vaccines Sales Forecast by Region (2025-2030) & (Units)
Table 65. Global Conjugate Vaccines Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas Conjugate Vaccines Sales Forecast by Country (2025-2030) & (Units)
Table 67. Americas Conjugate Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC Conjugate Vaccines Sales Forecast by Region (2025-2030) & (Units)
Table 69. APAC Conjugate Vaccines Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe Conjugate Vaccines Sales Forecast by Country (2025-2030) & (Units)
Table 71. Europe Conjugate Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa Conjugate Vaccines Sales Forecast by Country (2025-2030) & (Units)
Table 73. Middle East & Africa Conjugate Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global Conjugate Vaccines Sales Forecast by Type (2025-2030) & (Units)
Table 75. Global Conjugate Vaccines Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global Conjugate Vaccines Sales Forecast by Application (2025-2030) & (Units)
Table 77. Global Conjugate Vaccines Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. Novartis Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 79. Novartis Conjugate Vaccines Product Portfolios and Specifications
Table 80. Novartis Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 81. Novartis Main Business
Table 82. Novartis Latest Developments
Table 83. Neuron Biotech Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 84. Neuron Biotech Conjugate Vaccines Product Portfolios and Specifications
Table 85. Neuron Biotech Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 86. Neuron Biotech Main Business
Table 87. Neuron Biotech Latest Developments
Table 88. Serum Institute of India Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 89. Serum Institute of India Conjugate Vaccines Product Portfolios and Specifications
Table 90. Serum Institute of India Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 91. Serum Institute of India Main Business
Table 92. Serum Institute of India Latest Developments
Table 93. Pfizer Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer Conjugate Vaccines Product Portfolios and Specifications
Table 95. Pfizer Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 96. Pfizer Main Business
Table 97. Pfizer Latest Developments
Table 98. Sanofi Pasteur Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 99. Sanofi Pasteur Conjugate Vaccines Product Portfolios and Specifications
Table 100. Sanofi Pasteur Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 101. Sanofi Pasteur Main Business
Table 102. Sanofi Pasteur Latest Developments
Table 103. Bharat Biotech Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 104. Bharat Biotech Conjugate Vaccines Product Portfolios and Specifications
Table 105. Bharat Biotech Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 106. Bharat Biotech Main Business
Table 107. Bharat Biotech Latest Developments
Table 108. Biological Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 109. Biological Conjugate Vaccines Product Portfolios and Specifications
Table 110. Biological Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 111. Biological Main Business
Table 112. Biological Latest Developments
Table 113. GlaxoSmithKline Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 114. GlaxoSmithKline Conjugate Vaccines Product Portfolios and Specifications
Table 115. GlaxoSmithKline Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 116. GlaxoSmithKline Main Business
Table 117. GlaxoSmithKline Latest Developments
Table 118. Merck Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 119. Merck Conjugate Vaccines Product Portfolios and Specifications
Table 120. Merck Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 121. Merck Main Business
Table 122. Merck Latest Developments
Table 123. CSL Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 124. CSL Conjugate Vaccines Product Portfolios and Specifications
Table 125. CSL Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 126. CSL Main Business
Table 127. CSL Latest Developments
Table 1. Conjugate Vaccines Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Conjugate Vaccines Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Monovalent Conjugate Vaccines
Table 4. Major Players of Multivalent Conjugate Vaccines
Table 5. Global Conjugate Vaccines Sales by Type (2019-2024) & (Units)
Table 6. Global Conjugate Vaccines Sales Market Share by Type (2019-2024)
Table 7. Global Conjugate Vaccines Revenue by Type (2019-2024) & ($ million)
Table 8. Global Conjugate Vaccines Revenue Market Share by Type (2019-2024)
Table 9. Global Conjugate Vaccines Sale Price by Type (2019-2024) & (USD/Unit)
Table 10. Global Conjugate Vaccines Sales by Application (2019-2024) & (Units)
Table 11. Global Conjugate Vaccines Sales Market Share by Application (2019-2024)
Table 12. Global Conjugate Vaccines Revenue by Application (2019-2024)
Table 13. Global Conjugate Vaccines Revenue Market Share by Application (2019-2024)
Table 14. Global Conjugate Vaccines Sale Price by Application (2019-2024) & (USD/Unit)
Table 15. Global Conjugate Vaccines Sales by Company (2019-2024) & (Units)
Table 16. Global Conjugate Vaccines Sales Market Share by Company (2019-2024)
Table 17. Global Conjugate Vaccines Revenue by Company (2019-2024) ($ Millions)
Table 18. Global Conjugate Vaccines Revenue Market Share by Company (2019-2024)
Table 19. Global Conjugate Vaccines Sale Price by Company (2019-2024) & (USD/Unit)
Table 20. Key Manufacturers Conjugate Vaccines Producing Area Distribution and Sales Area
Table 21. Players Conjugate Vaccines Products Offered
Table 22. Conjugate Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Conjugate Vaccines Sales by Geographic Region (2019-2024) & (Units)
Table 26. Global Conjugate Vaccines Sales Market Share Geographic Region (2019-2024)
Table 27. Global Conjugate Vaccines Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Conjugate Vaccines Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Conjugate Vaccines Sales by Country/Region (2019-2024) & (Units)
Table 30. Global Conjugate Vaccines Sales Market Share by Country/Region (2019-2024)
Table 31. Global Conjugate Vaccines Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Conjugate Vaccines Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Conjugate Vaccines Sales by Country (2019-2024) & (Units)
Table 34. Americas Conjugate Vaccines Sales Market Share by Country (2019-2024)
Table 35. Americas Conjugate Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas Conjugate Vaccines Revenue Market Share by Country (2019-2024)
Table 37. Americas Conjugate Vaccines Sales by Type (2019-2024) & (Units)
Table 38. Americas Conjugate Vaccines Sales by Application (2019-2024) & (Units)
Table 39. APAC Conjugate Vaccines Sales by Region (2019-2024) & (Units)
Table 40. APAC Conjugate Vaccines Sales Market Share by Region (2019-2024)
Table 41. APAC Conjugate Vaccines Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC Conjugate Vaccines Revenue Market Share by Region (2019-2024)
Table 43. APAC Conjugate Vaccines Sales by Type (2019-2024) & (Units)
Table 44. APAC Conjugate Vaccines Sales by Application (2019-2024) & (Units)
Table 45. Europe Conjugate Vaccines Sales by Country (2019-2024) & (Units)
Table 46. Europe Conjugate Vaccines Sales Market Share by Country (2019-2024)
Table 47. Europe Conjugate Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe Conjugate Vaccines Revenue Market Share by Country (2019-2024)
Table 49. Europe Conjugate Vaccines Sales by Type (2019-2024) & (Units)
Table 50. Europe Conjugate Vaccines Sales by Application (2019-2024) & (Units)
Table 51. Middle East & Africa Conjugate Vaccines Sales by Country (2019-2024) & (Units)
Table 52. Middle East & Africa Conjugate Vaccines Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa Conjugate Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa Conjugate Vaccines Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa Conjugate Vaccines Sales by Type (2019-2024) & (Units)
Table 56. Middle East & Africa Conjugate Vaccines Sales by Application (2019-2024) & (Units)
Table 57. Key Market Drivers & Growth Opportunities of Conjugate Vaccines
Table 58. Key Market Challenges & Risks of Conjugate Vaccines
Table 59. Key Industry Trends of Conjugate Vaccines
Table 60. Conjugate Vaccines Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Conjugate Vaccines Distributors List
Table 63. Conjugate Vaccines Customer List
Table 64. Global Conjugate Vaccines Sales Forecast by Region (2025-2030) & (Units)
Table 65. Global Conjugate Vaccines Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas Conjugate Vaccines Sales Forecast by Country (2025-2030) & (Units)
Table 67. Americas Conjugate Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC Conjugate Vaccines Sales Forecast by Region (2025-2030) & (Units)
Table 69. APAC Conjugate Vaccines Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe Conjugate Vaccines Sales Forecast by Country (2025-2030) & (Units)
Table 71. Europe Conjugate Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa Conjugate Vaccines Sales Forecast by Country (2025-2030) & (Units)
Table 73. Middle East & Africa Conjugate Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global Conjugate Vaccines Sales Forecast by Type (2025-2030) & (Units)
Table 75. Global Conjugate Vaccines Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global Conjugate Vaccines Sales Forecast by Application (2025-2030) & (Units)
Table 77. Global Conjugate Vaccines Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. Novartis Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 79. Novartis Conjugate Vaccines Product Portfolios and Specifications
Table 80. Novartis Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 81. Novartis Main Business
Table 82. Novartis Latest Developments
Table 83. Neuron Biotech Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 84. Neuron Biotech Conjugate Vaccines Product Portfolios and Specifications
Table 85. Neuron Biotech Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 86. Neuron Biotech Main Business
Table 87. Neuron Biotech Latest Developments
Table 88. Serum Institute of India Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 89. Serum Institute of India Conjugate Vaccines Product Portfolios and Specifications
Table 90. Serum Institute of India Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 91. Serum Institute of India Main Business
Table 92. Serum Institute of India Latest Developments
Table 93. Pfizer Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer Conjugate Vaccines Product Portfolios and Specifications
Table 95. Pfizer Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 96. Pfizer Main Business
Table 97. Pfizer Latest Developments
Table 98. Sanofi Pasteur Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 99. Sanofi Pasteur Conjugate Vaccines Product Portfolios and Specifications
Table 100. Sanofi Pasteur Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 101. Sanofi Pasteur Main Business
Table 102. Sanofi Pasteur Latest Developments
Table 103. Bharat Biotech Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 104. Bharat Biotech Conjugate Vaccines Product Portfolios and Specifications
Table 105. Bharat Biotech Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 106. Bharat Biotech Main Business
Table 107. Bharat Biotech Latest Developments
Table 108. Biological Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 109. Biological Conjugate Vaccines Product Portfolios and Specifications
Table 110. Biological Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 111. Biological Main Business
Table 112. Biological Latest Developments
Table 113. GlaxoSmithKline Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 114. GlaxoSmithKline Conjugate Vaccines Product Portfolios and Specifications
Table 115. GlaxoSmithKline Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 116. GlaxoSmithKline Main Business
Table 117. GlaxoSmithKline Latest Developments
Table 118. Merck Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 119. Merck Conjugate Vaccines Product Portfolios and Specifications
Table 120. Merck Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 121. Merck Main Business
Table 122. Merck Latest Developments
Table 123. CSL Basic Information, Conjugate Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 124. CSL Conjugate Vaccines Product Portfolios and Specifications
Table 125. CSL Conjugate Vaccines Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 126. CSL Main Business
Table 127. CSL Latest Developments
LIST OF FIGURES
Figure 1. Picture of Conjugate Vaccines
Figure 2. Conjugate Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Conjugate Vaccines Sales Growth Rate 2019-2030 (Units)
Figure 7. Global Conjugate Vaccines Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Conjugate Vaccines Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Monovalent Conjugate Vaccines
Figure 10. Product Picture of Multivalent Conjugate Vaccines
Figure 11. Global Conjugate Vaccines Sales Market Share by Type in 2023
Figure 12. Global Conjugate Vaccines Revenue Market Share by Type (2019-2024)
Figure 13. Conjugate Vaccines Consumed in Children
Figure 14. Global Conjugate Vaccines Market: Children (2019-2024) & (Units)
Figure 15. Conjugate Vaccines Consumed in Adults
Figure 16. Global Conjugate Vaccines Market: Adults (2019-2024) & (Units)
Figure 17. Global Conjugate Vaccines Sales Market Share by Application (2023)
Figure 18. Global Conjugate Vaccines Revenue Market Share by Application in 2023
Figure 19. Conjugate Vaccines Sales Market by Company in 2023 (Units)
Figure 20. Global Conjugate Vaccines Sales Market Share by Company in 2023
Figure 21. Conjugate Vaccines Revenue Market by Company in 2023 ($ Million)
Figure 22. Global Conjugate Vaccines Revenue Market Share by Company in 2023
Figure 23. Global Conjugate Vaccines Sales Market Share by Geographic Region (2019-2024)
Figure 24. Global Conjugate Vaccines Revenue Market Share by Geographic Region in 2023
Figure 25. Americas Conjugate Vaccines Sales 2019-2024 (Units)
Figure 26. Americas Conjugate Vaccines Revenue 2019-2024 ($ Millions)
Figure 27. APAC Conjugate Vaccines Sales 2019-2024 (Units)
Figure 28. APAC Conjugate Vaccines Revenue 2019-2024 ($ Millions)
Figure 29. Europe Conjugate Vaccines Sales 2019-2024 (Units)
Figure 30. Europe Conjugate Vaccines Revenue 2019-2024 ($ Millions)
Figure 31. Middle East & Africa Conjugate Vaccines Sales 2019-2024 (Units)
Figure 32. Middle East & Africa Conjugate Vaccines Revenue 2019-2024 ($ Millions)
Figure 33. Americas Conjugate Vaccines Sales Market Share by Country in 2023
Figure 34. Americas Conjugate Vaccines Revenue Market Share by Country in 2023
Figure 35. Americas Conjugate Vaccines Sales Market Share by Type (2019-2024)
Figure 36. Americas Conjugate Vaccines Sales Market Share by Application (2019-2024)
Figure 37. United States Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 38. Canada Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 39. Mexico Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 40. Brazil Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 41. APAC Conjugate Vaccines Sales Market Share by Region in 2023
Figure 42. APAC Conjugate Vaccines Revenue Market Share by Regions in 2023
Figure 43. APAC Conjugate Vaccines Sales Market Share by Type (2019-2024)
Figure 44. APAC Conjugate Vaccines Sales Market Share by Application (2019-2024)
Figure 45. China Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 46. Japan Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 47. South Korea Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 48. Southeast Asia Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 49. India Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 50. Australia Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 51. China Taiwan Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 52. Europe Conjugate Vaccines Sales Market Share by Country in 2023
Figure 53. Europe Conjugate Vaccines Revenue Market Share by Country in 2023
Figure 54. Europe Conjugate Vaccines Sales Market Share by Type (2019-2024)
Figure 55. Europe Conjugate Vaccines Sales Market Share by Application (2019-2024)
Figure 56. Germany Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 57. France Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 58. UK Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 59. Italy Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 60. Russia Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 61. Middle East & Africa Conjugate Vaccines Sales Market Share by Country in 2023
Figure 62. Middle East & Africa Conjugate Vaccines Revenue Market Share by Country in 2023
Figure 63. Middle East & Africa Conjugate Vaccines Sales Market Share by Type (2019-2024)
Figure 64. Middle East & Africa Conjugate Vaccines Sales Market Share by Application (2019-2024)
Figure 65. Egypt Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 66. South Africa Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 67. Israel Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 68. Turkey Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 69. GCC Country Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Conjugate Vaccines in 2023
Figure 71. Manufacturing Process Analysis of Conjugate Vaccines
Figure 72. Industry Chain Structure of Conjugate Vaccines
Figure 73. Channels of Distribution
Figure 74. Global Conjugate Vaccines Sales Market Forecast by Region (2025-2030)
Figure 75. Global Conjugate Vaccines Revenue Market Share Forecast by Region (2025-2030)
Figure 76. Global Conjugate Vaccines Sales Market Share Forecast by Type (2025-2030)
Figure 77. Global Conjugate Vaccines Revenue Market Share Forecast by Type (2025-2030)
Figure 78. Global Conjugate Vaccines Sales Market Share Forecast by Application (2025-2030)
Figure 79. Global Conjugate Vaccines Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Conjugate Vaccines
Figure 2. Conjugate Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Conjugate Vaccines Sales Growth Rate 2019-2030 (Units)
Figure 7. Global Conjugate Vaccines Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Conjugate Vaccines Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Monovalent Conjugate Vaccines
Figure 10. Product Picture of Multivalent Conjugate Vaccines
Figure 11. Global Conjugate Vaccines Sales Market Share by Type in 2023
Figure 12. Global Conjugate Vaccines Revenue Market Share by Type (2019-2024)
Figure 13. Conjugate Vaccines Consumed in Children
Figure 14. Global Conjugate Vaccines Market: Children (2019-2024) & (Units)
Figure 15. Conjugate Vaccines Consumed in Adults
Figure 16. Global Conjugate Vaccines Market: Adults (2019-2024) & (Units)
Figure 17. Global Conjugate Vaccines Sales Market Share by Application (2023)
Figure 18. Global Conjugate Vaccines Revenue Market Share by Application in 2023
Figure 19. Conjugate Vaccines Sales Market by Company in 2023 (Units)
Figure 20. Global Conjugate Vaccines Sales Market Share by Company in 2023
Figure 21. Conjugate Vaccines Revenue Market by Company in 2023 ($ Million)
Figure 22. Global Conjugate Vaccines Revenue Market Share by Company in 2023
Figure 23. Global Conjugate Vaccines Sales Market Share by Geographic Region (2019-2024)
Figure 24. Global Conjugate Vaccines Revenue Market Share by Geographic Region in 2023
Figure 25. Americas Conjugate Vaccines Sales 2019-2024 (Units)
Figure 26. Americas Conjugate Vaccines Revenue 2019-2024 ($ Millions)
Figure 27. APAC Conjugate Vaccines Sales 2019-2024 (Units)
Figure 28. APAC Conjugate Vaccines Revenue 2019-2024 ($ Millions)
Figure 29. Europe Conjugate Vaccines Sales 2019-2024 (Units)
Figure 30. Europe Conjugate Vaccines Revenue 2019-2024 ($ Millions)
Figure 31. Middle East & Africa Conjugate Vaccines Sales 2019-2024 (Units)
Figure 32. Middle East & Africa Conjugate Vaccines Revenue 2019-2024 ($ Millions)
Figure 33. Americas Conjugate Vaccines Sales Market Share by Country in 2023
Figure 34. Americas Conjugate Vaccines Revenue Market Share by Country in 2023
Figure 35. Americas Conjugate Vaccines Sales Market Share by Type (2019-2024)
Figure 36. Americas Conjugate Vaccines Sales Market Share by Application (2019-2024)
Figure 37. United States Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 38. Canada Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 39. Mexico Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 40. Brazil Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 41. APAC Conjugate Vaccines Sales Market Share by Region in 2023
Figure 42. APAC Conjugate Vaccines Revenue Market Share by Regions in 2023
Figure 43. APAC Conjugate Vaccines Sales Market Share by Type (2019-2024)
Figure 44. APAC Conjugate Vaccines Sales Market Share by Application (2019-2024)
Figure 45. China Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 46. Japan Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 47. South Korea Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 48. Southeast Asia Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 49. India Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 50. Australia Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 51. China Taiwan Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 52. Europe Conjugate Vaccines Sales Market Share by Country in 2023
Figure 53. Europe Conjugate Vaccines Revenue Market Share by Country in 2023
Figure 54. Europe Conjugate Vaccines Sales Market Share by Type (2019-2024)
Figure 55. Europe Conjugate Vaccines Sales Market Share by Application (2019-2024)
Figure 56. Germany Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 57. France Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 58. UK Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 59. Italy Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 60. Russia Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 61. Middle East & Africa Conjugate Vaccines Sales Market Share by Country in 2023
Figure 62. Middle East & Africa Conjugate Vaccines Revenue Market Share by Country in 2023
Figure 63. Middle East & Africa Conjugate Vaccines Sales Market Share by Type (2019-2024)
Figure 64. Middle East & Africa Conjugate Vaccines Sales Market Share by Application (2019-2024)
Figure 65. Egypt Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 66. South Africa Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 67. Israel Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 68. Turkey Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 69. GCC Country Conjugate Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Conjugate Vaccines in 2023
Figure 71. Manufacturing Process Analysis of Conjugate Vaccines
Figure 72. Industry Chain Structure of Conjugate Vaccines
Figure 73. Channels of Distribution
Figure 74. Global Conjugate Vaccines Sales Market Forecast by Region (2025-2030)
Figure 75. Global Conjugate Vaccines Revenue Market Share Forecast by Region (2025-2030)
Figure 76. Global Conjugate Vaccines Sales Market Share Forecast by Type (2025-2030)
Figure 77. Global Conjugate Vaccines Revenue Market Share Forecast by Type (2025-2030)
Figure 78. Global Conjugate Vaccines Sales Market Share Forecast by Application (2025-2030)
Figure 79. Global Conjugate Vaccines Revenue Market Share Forecast by Application (2025-2030)
